Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry S Taylor

Showing results (61-70 of 144) with videos related to

Pageof 15
Sort By:
Nature|May 29, 2020
Phase and context shape the function of composite oncogenic mutationsAlexander N Gorelick, Francisco J Sánchez-Rivera, Yanyan Cai, et al.
Cancer Research|March 1, 2014
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependenceMoriah H Nissan, Christine A Pratilas, Alexis M Jones, et al.
Nature|August 8, 2017
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RASZhan Yao, Rona Yaeger, Vanessa S Rodrik-Outmezguine, et al.
Molecular Cancer Research : MCR|December 11, 2020
AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin SignalingSizhi Paul Gao, Amber J Kiliti, Kai Zhang, et al.
Science (New York, N.Y.)|August 28, 2012
Genome sequencing identifies a basis for everolimus sensitivityGopa Iyer, Aphrothiti J Hanrahan, Matthew I Milowsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in CancerSabine Topka, Zoe Steinsnyder, Vignesh Ravichandran, et al.
Cancer Discovery|September 12, 2015
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK InhibitionMaria E R Garcia-Rendueles, Julio C Ricarte-Filho, Brian R Untch, et al.
Nature Genetics|December 1, 2009
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignanciesSelvaraju Veeriah, Barry S Taylor, Shasha Meng, et al.
Cancer Cell|August 16, 2011
Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progressionMuhan Chen, Christopher P Pratt, Martha E Zeeman, et al.
Cancer Research|June 24, 2010
Genomic and biological characterization of exon 4 KRAS mutations in human cancerManickam Janakiraman, Efsevia Vakiani, Zhaoshi Zeng, et al.
Pageof 15

Showing results (61-70 of 144) with videos related to

Sort By:
Pageof 15
Nature|May 29, 2020
Phase and context shape the function of composite oncogenic mutationsAlexander N Gorelick, Francisco J Sánchez-Rivera, Yanyan Cai, et al.
Cancer Research|March 1, 2014
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependenceMoriah H Nissan, Christine A Pratilas, Alexis M Jones, et al.
Nature|August 8, 2017
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RASZhan Yao, Rona Yaeger, Vanessa S Rodrik-Outmezguine, et al.
Molecular Cancer Research : MCR|December 11, 2020
AKT1 E17K Inhibits Cancer Cell Migration by Abrogating β-Catenin SignalingSizhi Paul Gao, Amber J Kiliti, Kai Zhang, et al.
Science (New York, N.Y.)|August 28, 2012
Genome sequencing identifies a basis for everolimus sensitivityGopa Iyer, Aphrothiti J Hanrahan, Matthew I Milowsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in CancerSabine Topka, Zoe Steinsnyder, Vignesh Ravichandran, et al.
Cancer Discovery|September 12, 2015
NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK InhibitionMaria E R Garcia-Rendueles, Julio C Ricarte-Filho, Brian R Untch, et al.
Nature Genetics|December 1, 2009
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignanciesSelvaraju Veeriah, Barry S Taylor, Shasha Meng, et al.
Cancer Cell|August 16, 2011
Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progressionMuhan Chen, Christopher P Pratt, Martha E Zeeman, et al.
Cancer Research|June 24, 2010
Genomic and biological characterization of exon 4 KRAS mutations in human cancerManickam Janakiraman, Efsevia Vakiani, Zhaoshi Zeng, et al.
Pageof 15